Table 4.

Summary of AEs by GVS in older (≥70 years old) patients receiving olaparib plus bevacizumab.

AEs	GVS = 0 (n = 34)	GVS ≥ 1 (n = 48)
Grade ≥3	21 (61.8)	35 (72.9)
Serious AEs	12 (35.3)	21 (43.8)
Leading to dose interruption	17 (50.0)	32 (66.7)
Leading to dose reduction	12 (35.3)	26 (54.2)
Leading to discontinuation	10 (29.4)	13 (27.1)
Leading to death	0 (0)	0 (0)

Data are n (%) unless otherwise stated. Relationship to the indicated agent was assessed by the investigator. AEs were graded according to the CTCAE, version 4.03.

Abbreviations: AE, adverse event; CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; GVS, Geriatric Vulnerability Score.